What you don't know about Thermo Fisher's capabilities in clinical research, cold chain, and biologics.
 
What you don't know about Thermo Fisher's capabilities in manufacturing and biologics. | View web version
 
     
 
Special Edition
 
     
     
  News from THERMO FISHER SCIENTIFIC
     
     
     
 
Manufacturing
 
Thermo Fisher’s Florence Site On Track For Commercial Spray Drying Services
 
 
Formulation challenges for enhancing the bioavailability of poorly soluble API’s can be solved by spray drying. Thermo Fisher’s Pharma Services is on track for operational availability of their Florence (East), South Carolina, commercial spray drying facility in July 2019.
 
 
 
 
 
     
 
speed to market
 
Thermo Fisher Scientific's Quick-to-Clinic™ For OSD – Milton Park, UK, And Horsham Sites Deliver Phase I Clinical Trial Material In 14 Weeks For Reneo Pharmaceuticals
 
 
When developing new pharmaceutical products, it is very important to get to the Phase I clinical trial in a fast, efficient and cost-effective way. With its oral solid dose Quick-to-Clinic™ program, Thermo Fisher Scientific can deliver a prospective drug in a phase-appropriate formulation for first-in-human studies in as little as 14 weeks.
 
 
 
 
 
     
 
Acquisition
 
Thermo Fisher Scientific Completes Acquisition Of Brammer Bio
 
 
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash.  The completion of the transaction follows the receipt of all required regulatory approvals.
 
 
 
 
 
     
 
Acquisition
 
Thermo Fisher Scientific To Acquire Manufacturing Site In Cork, Ireland, From GSK
 
 
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs).
 
 
 
 
 
     
     
     
  Ensure our newsletter reaches your inbox by following these whitelist instructions. If you need to update your user profile, please visit here.

This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out here. You may also send an e-mail to newsletter@vertmarkets.com.

© Copyright 2019 {{my.Member_Addr}}. All rights reserved. All product names contained herein are the trademarks of their respective holders.